Abnormalities in the genes that encode Large Amino Acid Transporters increase the risk of Autism Spectrum Disorder.


Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
01 2020
Historique:
received: 16 07 2019
revised: 08 10 2019
accepted: 16 10 2019
pubmed: 9 11 2019
medline: 27 3 2021
entrez: 9 11 2019
Statut: ppublish

Résumé

Autism spectrum disorder (ASD) is a common neurodevelopmental disorder whose molecular mechanisms are largely unknown. Several studies have shown an association between ASD and abnormalities in the metabolism of amino acids, specifically tryptophan and branched-chain amino acids (BCAAs). Ninety-seven patients with ASD were screened by Sanger sequencing the genes encoding the heavy (SLC3A2) and light subunits (SLC7A5 and SLC7A8) of the large amino acid transporters (LAT) 1 and 2. LAT1 and 2 are responsible for the transportation of tryptophan and BCAA across the blood-brain barrier and are expressed both in blood and brain. Functional studies were performed employing the Biolog Phenotype Microarray Mammalian (PM-M) technology to investigate the metabolic profiling in lymphoblastoid cell lines from 43 patients with ASD and 50 controls with particular focus on the amino acid substrates of LATs. We detected nine likely pathogenic variants in 11 of 97 patients (11.3%): three in SLC3A2, three in SLC7A5, and three in SLC7A8. Six variants of unknown significance were detected in eight patients, two of which also carrying a likely pathogenic variant. The functional studies showed a consistently reduced utilization of tryptophan, accompanied by evidence of reduced utilization of other large aromatic amino acids (LAAs), either alone or as part of a dipeptide. Coding variants in the LAT genes were detected in 17 of 97 patients with ASD (17.5%). Metabolic assays indicate that such abnormalities affect the utilization of certain amino acids, particularly tryptophan and other LAAs, with potential consequences on their transport across the blood barrier and their availability during brain development. Therefore, abnormalities in the LAT1 and two transporters are likely associated with an increased risk of developing ASD.

Sections du résumé

BACKGROUND
Autism spectrum disorder (ASD) is a common neurodevelopmental disorder whose molecular mechanisms are largely unknown. Several studies have shown an association between ASD and abnormalities in the metabolism of amino acids, specifically tryptophan and branched-chain amino acids (BCAAs).
METHODS
Ninety-seven patients with ASD were screened by Sanger sequencing the genes encoding the heavy (SLC3A2) and light subunits (SLC7A5 and SLC7A8) of the large amino acid transporters (LAT) 1 and 2. LAT1 and 2 are responsible for the transportation of tryptophan and BCAA across the blood-brain barrier and are expressed both in blood and brain. Functional studies were performed employing the Biolog Phenotype Microarray Mammalian (PM-M) technology to investigate the metabolic profiling in lymphoblastoid cell lines from 43 patients with ASD and 50 controls with particular focus on the amino acid substrates of LATs.
RESULTS
We detected nine likely pathogenic variants in 11 of 97 patients (11.3%): three in SLC3A2, three in SLC7A5, and three in SLC7A8. Six variants of unknown significance were detected in eight patients, two of which also carrying a likely pathogenic variant. The functional studies showed a consistently reduced utilization of tryptophan, accompanied by evidence of reduced utilization of other large aromatic amino acids (LAAs), either alone or as part of a dipeptide.
CONCLUSION
Coding variants in the LAT genes were detected in 17 of 97 patients with ASD (17.5%). Metabolic assays indicate that such abnormalities affect the utilization of certain amino acids, particularly tryptophan and other LAAs, with potential consequences on their transport across the blood barrier and their availability during brain development. Therefore, abnormalities in the LAT1 and two transporters are likely associated with an increased risk of developing ASD.

Identifiants

pubmed: 31701662
doi: 10.1002/mgg3.1036
pmc: PMC6978257
doi:

Substances chimiques

Amino Acid Transport System y+ 0
Fusion Regulatory Protein 1, Heavy Chain 0
Fusion Regulatory Protein 1, Light Chains 0
Large Neutral Amino Acid-Transporter 1 0
SLC3A2 protein, human 0
SLC7A5 protein, human 0
SLC7A8 protein, human 0
Tryptophan 8DUH1N11BX

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1036

Informations de copyright

© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.

Références

Curr Clin Pharmacol. 2014;9(4):326-34
pubmed: 24050742
Biol Psychiatry. 2019 Feb 15;85(4):345-354
pubmed: 30446206
Nat Genet. 2019 Jan;51(1):106-116
pubmed: 30559488
Metab Brain Dis. 2017 Oct;32(5):1585-1593
pubmed: 28608247
Nat Rev Drug Discov. 2002 Aug;1(8):609-20
pubmed: 12402501
J Neurochem. 2016 Dec;139(6):1081-1092
pubmed: 27365114
PLoS One. 2014 Nov 07;9(11):e112445
pubmed: 25380056
J Biol Chem. 1999 Jul 9;274(28):19738-44
pubmed: 10391915
Neuron. 2018 Feb 7;97(3):488-493
pubmed: 29420931
Neuroscience. 2016 May 3;321:24-41
pubmed: 26577932
Mol Genet Genomic Med. 2020 Jan;8(1):e1036
pubmed: 31701662
Genet Med. 2019 Jul;21(7):1611-1620
pubmed: 30504930
Cell. 2016 Dec 1;167(6):1481-1494.e18
pubmed: 27912058
Am J Med Genet. 1998 Apr 1;76(4):327-36
pubmed: 9545097
Mol Autism. 2013 Jun 03;4(1):16
pubmed: 23731516
Mol Autism. 2016 Nov 24;7:47
pubmed: 27904735
Mol Autism. 2018 Feb 19;9:3
pubmed: 29479405
BMC Bioinformatics. 2015 May 06;16:144
pubmed: 25943565
Science. 2012 Oct 19;338(6105):394-7
pubmed: 22956686
MMWR Surveill Summ. 2018 Apr 27;67(6):1-23
pubmed: 29701730
Nature. 1998 Sep 17;395(6699):288-91
pubmed: 9751058
Metab Brain Dis. 2018 Jun;33(3):843-854
pubmed: 29397522
PLoS One. 2011 Mar 24;6(3):e18147
pubmed: 21455318
Pflugers Arch. 2003 Feb;445(5):529-33
pubmed: 12634921
J Proteome Res. 2012 Dec 7;11(12):5856-62
pubmed: 23106572

Auteurs

Lauren Cascio (L)

JC Self research Institute, Greenwood Genetic Center, Greenwood, SC, USA.

Chin-Fu Chen (CF)

JC Self research Institute, Greenwood Genetic Center, Greenwood, SC, USA.

Rini Pauly (R)

JC Self research Institute, Greenwood Genetic Center, Greenwood, SC, USA.

Sujata Srikanth (S)

JC Self research Institute, Greenwood Genetic Center, Greenwood, SC, USA.

Kelly Jones (K)

JC Self research Institute, Greenwood Genetic Center, Greenwood, SC, USA.

Cindy D Skinner (CD)

JC Self research Institute, Greenwood Genetic Center, Greenwood, SC, USA.

Roger E Stevenson (RE)

JC Self research Institute, Greenwood Genetic Center, Greenwood, SC, USA.

Charles E Schwartz (CE)

JC Self research Institute, Greenwood Genetic Center, Greenwood, SC, USA.

Luigi Boccuto (L)

JC Self research Institute, Greenwood Genetic Center, Greenwood, SC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH